Abbott Sees Signs Of Post-Pandemic Recovery In Q2
Abbott’s medical device sales were down about 20% year-over-year in the second quarter of 2020, but diagnostics sales were up 7%. Procedure trends at the end of the second quarter suggest that demand for devices will soon recover to pre-pandemic levels.
You may also be interested in...
Abbott reported strong sales for diagnostics and devices in the third quarter and raised its full-year EPS guidance to $3.55 per share.
The new continuous glucose sensor is the smallest and thinnest in the world, according to Abbott.
FreeStyle Libre 2 is the only integrated continuous glucose monitoring system that continuously measures the user's blood glucose without fingersticks.